FDA Oncology Announcements

Anti-GD2 × Clear all

3 Announcements

FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow

Drug: DANYELZA (naxitamab) · Anti-GD2 antibody
Condition: CNS

FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow

Drug: DANYELZA (naxitamab) · Anti-GD2 antibody
Condition: CNS

Dinutuximab

Drug: Unituxin (dinutuximab) · Anti-GD2 antibody
Condition: Other